Allen Robert D. III 4

What Happened

• Robert D. Allen III, Chief Scientific Officer of Invivyd, was granted 625,000 derivative shares/options on 2026-01-29. The transaction is reported as an acquisition (grant) at a reported price of $0.00, meaning no cash was exchanged at grant.
• This grant does not represent an immediate sale or market purchase; it is a compensation award that will vest over time rather than an instant change in marketable stock holdings.

Key Details

• Transaction date: 2026-01-29; Filing date: 2026-01-30.
• Amount: 625,000 shares (derivative award) reported at $0.00 per share.
• Shares owned after transaction: Not specified in the provided filing summary.
• Vesting: The award vests over three years. Per the filing footnote, 1/36th of the shares vest in substantially equal monthly installments beginning one month after the grant date, subject to continued service.
• Timeliness: Filing appears timely (filed the day after the grant).

Context

• This was a compensation grant (derivative award/options/RSUs) rather than an open-market purchase or sale. Such grants are common for executives and are tied to retention and performance; they do not necessarily signal immediate bullish or bearish insider sentiment.
• Because vesting is spread monthly over three years, any future sales or exercises would be reported separately when they occur.